2023-05-05 11:16:50 ET
- Mind Medicine press release ( NASDAQ: MNMD ): Q1 GAAP EPS of -$0.65 misses by $0.22 .
- As of March 31, 2023, MindMed had cash and cash equivalents totaling $129.4 million compared to $142.1 million as of December 31, 2022. The Company believes its available cash and cash equivalents will be sufficient to fund its operating requirements into the first half of 2025.
- Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023
- MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting
- Strengthened leadership team with appointment of Mark R. Sullivan as Chief Legal Officer
For further details see:
Mind Medicine GAAP EPS of -$0.65 misses by $0.22